Free

New England CEPAC Meeting: Update to Psoriasis, Elagolix for Endometriosis

Event Information

Share this event

Date and Time

Location

Location

Communication & Creative Media (CCM) Building

Champlain College

375 Maple Street

Burlington, VT 05401

View Map

Event description

Description

The New England Comparative Effectiveness Public Advisory Council (CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), will hold a public meeting on July 12, 2018 to consider two areas of emerging therapies:

  1. Four new therapies for moderate-severe plaque psoriasis, and

  2. Elagolix for for treatment of Endometriosis.

In 2016, ICER issued its first report evaluating four distinct classes of drug therapies for treating moderate-severe plaque psoriasis. Since, a new class of treatment has emerged (IL23) and an existing drug is seeking a new indication for treating plaque psoriasis. During the morning of their 2018 meeting, ICER will evaluate Guselkumab (Tremfya®, Janssen/Johnson & Johnson), tildrakizumab (Ilumya®, Sun Pharma/Merck), risankizumab (Investigation, AbbVie) and certolizumab pegol (Cimzia®, UCB).

In the afternoon, ICER will evaluate elagolix (AbbVie) for management of endometriosis-associated pain. This is ICER's first review of this topic. Presentations of the evidence will be followed by a public comment period and deliberations and votes by the New England CEPAC. The votes will be followed by a policy roundtable.

A list of key dates for stakeholder engagement opportunities and other important information associated with the review of TOPIC therapies can be found on ICER's website at https://icer-review.org/topic/psoriasis/ for psoriasis and https://icer-review.org/topic/endometriosis/ for endometriosis.

Share with friends

Date and Time

Location

Communication & Creative Media (CCM) Building

Champlain College

375 Maple Street

Burlington, VT 05401

View Map

Save This Event

Event Saved